US Worldmeds LLC, of Louisville, Ky., said the FDA accepted and granted priority review of the NDA for lofexidine, an investigational product to mitigate symptoms associated with opioid withdrawal and facilitate completion of opioid discontinuation treatment. A PDUFA date for lofexidine, an oral, selective alpha 2-adrenergic receptor agonist, is expected in the second quarter of 2018.